A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines
Condition: Chikungunya Intervention: Biological: Chikungunya Sponsors: PaxVax, Inc.; Walter Reed Army Institute of Research (WRAIR) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials